MSD’s Keytruda has become the first checkpoint inhibitor to show improved survival when used as adjuvant therapy after surgery to remove tumours in clear cell renal cell carcinoma (RCC) patients. PD-1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback